课题基金 / 基金详情

AN ANALYSIS OF THE INHIBITION OF HIV-1 INFECTION BY CHEMOKINE-FC CHIMERA

AN ANALYSIS OF THE INHIBITION OF HIV-1 INFECTION BY CHEMOKINE-FC CHIMERA
趋化因子-FC嵌合体抑制HIV-1感染的分析
批准号:
12670287
负责人:
HIESHIMA Kunio
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

HIESHIMA Kunio的其他基金

相关文献

中文摘要
翻译
趋化因子受体CCR5和CXCR4分别是嗜巨噬细胞和嗜t细胞系HTV-1病毒分离株的主要共受体。因此,这些趋化因子受体是抗hiv药物的潜在靶点。然而,体内hiv - 1复制的不良反应和抑制作用尚不清楚。为了了解在体内阻断这些趋化因子受体的作用,我们生成了对其野生型趋化因子(即met-RANTES-Fc和P2G-SDF-l-Fc)以及野生型趋化因子fc嵌合体(即RANTES-Fc和SDF-l-Fc)具有拮抗活性的趋化因子fc嵌合体。尽管P2G-SDF-l-Fc在体外对SDF-1有明显的拮抗作用,但met-RANTES-Fc对RANTES没有拮抗作用。因此,我们将重点放在SDF-l-Fc嵌合体上,发现SDF-1-Fc和P2G-SDF-l-Fc在体外都具有抑制X4病毒复制的作用。BALB/c小鼠血液循环中SDF-1、SDF-l-Fc和P2G-SDF-l-Fc的表观半衰期分别为< h、4h和9h。小鼠腹腔注射P2G-SDF-l-Fc可显著降低B220+CD43;骨髓中的前B细胞和B220^IeM4未成熟B细胞,这与先前关于CXCR4缺陷小鼠的报道一致。然而,当这些嵌合体被注射到X4病毒感染后的人- pbl - scid小鼠体内时,与对照PBS处理相比,激动性SDF-l-Fc和拮抗性P2G-SDF-1-Fc都显著增强了病毒的复制,后者更强。这些嵌合体在体内促进HIV-1生长的机制目前尚不清楚,但这些数据表明,在体内阻断CXCR4应该谨慎考虑。
英文摘要
Chemokine receptors CCR5 and CXCR4 are the major co-receptors for macrophage tropic and T-cell line tropic HTV-1 viral isolates, respectively. Therefore, these chemokine receptors are potential targets for anti-HIV drugs. However, the adverse effect as well as the inhibitory effect of HIV-l replication in vivo remains unknown. To understand the effects of blocking these chemokine receptors in vivo, we generated chemokine-Fc chimeras with antagonistic activity against their wild-type chemokines (i.e. met-RANTES-Fc and P2G-SDF-l-Fc) as well as wild-type chemokine-Fc chimeras (i.e. RANTES-Fc and SDF-l-Fc). Although significant antagonistic activity was observed for P2G-SDF-l-Fc against SDF-1 in vitro, met-RANTES-Fc had no antagonistic effect against RANTES. Therefore, we focused on SDF-l-Fc chimeras, and found that both SDF-1-Fc and P2G-SDF-l-Fc had inhibitory effect of X4 virus replication in vitro. The apparent half-lives of SDF-1, SDF-l-Fc, and P2G-SDF-l-Fc in the blood circulation of BALB/c mice were about <lh, 4h and 9h, respectively. Intraperitoneal injection of P2G-SDF-l-Fc into mice caused significant reduction of B220+CD43; pre-B cells and B220^IeM4 Immature B cells in the bone marrow, which is in agreement with the previous reports of CXCR4 deficient mice. However, when these chimeras were injected into the human-PBL-SCID mice after infection of X4 virus, there was a dramatic enhancement of virus replication by both agonistic SDF-l-Fc and antagonistic P2G-SDF-1-Fc, more strongly in the latter, in contrast to the control PBS treatment. The mechanism of promotion of HIV-1 growth in vivo by these chimeras is not known at present, but these data implicated that blocking CXCR4 in vivo should be considered carefully.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
稗島州雄, 義江 修: "ケモカインレセプタ-とHIV感染症"日本臨牀特集「HIV/AIDS研究の進歩」. 60・4(in press). (2002)
Shuo Hijima、Osamu Yoshie:“趋化因子受体和 HIV 感染”日本临床试验“HIV/AIDS 研究进展”特刊 60・4(印刷中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nomiyama H, Hieshima K, et al.: "Human CC chemokine liver-expressed chemokine/CCL1 6 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes"International Immunology. 13・8. 1021-1029 (2001)
Nomiyama H、Hieshima K 等人:“人 CC 趋化因子肝脏表达的趋化因子/CCL1 6 是 CCR1、CCR2 和 CCR5 的功能性配体,由肝细胞组成型表达”国际免疫学 13・8(2001 年)。 )
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
HIESHIMA, K AND YOSH1E, O: "CHEMOKINE RECEPTORS AND HTV-1 INFECTION"NIPPON RINSHO. 60(4), (IN PRESS). (2002)
HIESHIMA, K 和 YOSH1E, O:“趋化因子受体和 HTV-1 感染”NIPPON RINSHO。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 6 条
    ROLE OF TRANSCRIPTION FACTOR C-MAF IN THE HTLV-1 LATENT INFECTION
    • 批准号:
      18590457
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.43万
    • 财政年份:
      2006
    • 负责人:
      HIESHIMA Kunio
    • 依托单位:
    CCL28 Has a Dual Role in Mucosal Immunity as Chemokine with a Broad-Spectrum Antimicrobial Activity
    • 批准号:
      14570289
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.86万
    • 财政年份:
      2002
    • 负责人:
      HIESHIMA Kunio
    • 依托单位: